Market Place
Sourcing Support
Insmed To Present At May 2026 Investor Conferences
30 Apr 2026 //
PR NEWSWIRE
Insmed To Host Q1 2026 Financial Results Conference Call On May 7
23 Apr 2026 //
PR NEWSWIRE
Insmed Discloses Inducement Grants Per NASDAQ LR 5635(C)(4)
05 Mar 2026 //
PR NEWSWIRE
Insmed Releases 2025 Financial Results & Business Update
19 Feb 2026 //
PR NEWSWIRE
Insmed Forecasts Sales of Brinsupri will reach $1B in 2026
19 Feb 2026 //
FIERCE PHARMA
Insmed To Present At March 2026 Investor Conferences
13 Feb 2026 //
PR NEWSWIRE
Insmed Updates Business At J.P. Morgan Healthcare Conference
09 Jan 2026 //
PR NEWSWIRE
Insmed Scrap Develop of Sinus Drug After Mid-Stage Study Failure
17 Dec 2025 //
REUTERS
Insmed Discloses Inducement Grants Per NASDAQ LR 5635(C)(4)
04 Dec 2025 //
PR NEWSWIRE
EU Approves Brinsupri as First Non-CF Bronchiectasis Therapy
18 Nov 2025 //
PR NEWSWIRE
Insmed Boosts Global Communities On 4th Annual Day Of Good
13 Nov 2025 //
PR NEWSWIRE
Insmed To Present at Nov & Dec 2025 Investor Conferences
05 Nov 2025 //
PR NEWSWIRE
Insmed Ranks No. 1 On Science`s 2025 Top Biopharma Employers List
24 Oct 2025 //
PR NEWSWIRE
Insmed Schedules Q3 2025 Financial Results Call
15 Oct 2025 //
PR NEWSWIRE
Insmed To Showcase Several Abstracts At ERS Congress 2025
22 Sep 2025 //
PR NEWSWIRE
Insmed Set to Present at September Investor Conferences
21 Aug 2025 //
PR NEWSWIRE
Insmed`s Brinsupri Nabs Landmark FDA Nod in Chronic Lung Disease
13 Aug 2025 //
PRESS RELEASE
Insmed Plans $650M Public Offering of Stock
11 Jun 2025 //
PR NEWSWIRE
Insmed Prices $750M Public Stock Offering
11 Jun 2025 //
PR NEWSWIRE
Insmed to Present at 2025 Goldman Sachs Healthcare Conference
28 May 2025 //
PR NEWSWIRE
Brensocatib Effective Across Subgroups in ASPEN Study
21 May 2025 //
PR NEWSWIRE
Insmed Reports Q1 2025 Financial Results and Business Update
08 May 2025 //
PR NEWSWIRE
Insmed to Present at BofA Securities 2025 Health Care Conference
29 Apr 2025 //
PR NEWSWIRE
Insmed: FDA Won`t Hold Meeting for Brensocatib Application
24 Feb 2025 //
PR NEWSWIRE
Insmed Reports Q4 & FY24 Results, Provides Business Update
20 Feb 2025 //
PR NEWSWIRE
Insmed to Host Q4 & Full-Year 2024 Financial Results Call on Feb 20
10 Feb 2025 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ LR 5635(c)(4)
03 Jan 2025 //
PR NEWSWIRE
Insmed To Present at 43rd Annual J.P. Morgan Conference
02 Jan 2025 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Rule 5635(c)(4)
07 Nov 2024 //
PR NEWSWIRE
Insmed Reports Q3 2024 Results and Business Update
31 Oct 2024 //
PR NEWSWIRE
Insmed Ranks No. 1 on Science`s 2024 Top Biopharma Employers List
24 Oct 2024 //
PR NEWSWIRE
Insmed To Host Q3 2024 Financial Results Conference Call On Oct 31
17 Oct 2024 //
PR NEWSWIRE
New Subgroup Analyses From Landmark Phase 3 ASPEN of Brensocatib
08 Oct 2024 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06 Sep 2024 //
PR NEWSWIRE
Insmed Reports Q2 2024 Results And Provides Business Update
08 Aug 2024 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
02 Aug 2024 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 Jul 2024 //
PR NEWSWIRE
New Positive Data From Brensocatib Study To Be Presented At Conference
03 Jul 2024 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07 Jun 2024 //
PR NEWSWIRE
Insmed to Host Commercial Webinar on June 4, 2024
30 May 2024 //
PR NEWSWIRE
Insmed Announces Pricing of $650 Million Public Offering of Common Stock
30 May 2024 //
PR NEWSWIRE
Insmed shares double as lung drug data convince Wall Street
29 May 2024 //
BIOPHRAMADIVE
Insmed: Positive Topline ASPEN Data For Brensocatib In Bronchiectasis
28 May 2024 //
PR NEWSWIRE
Insmed Announces Proposed $500 Million Public Offering of Common Stock
28 May 2024 //
PR NEWSWIRE
Insmed Presents ARIKAYCE NTM PRO, Microbiology Data At ATS
20 May 2024 //
PR NEWSWIRE
Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
09 May 2024 //
PR NEWSWIRE
Insmed to Host Q1 2024 Results Call on May 9
25 Apr 2024 //
PRESS RELEASE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 Apr 2024 //
PR NEWSWIRE
Insmed to Present Data from Across its Respiratory Portfolio at the Conference
27 Mar 2024 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 Mar 2024 //
PR NEWSWIRE
Insmed encourages people to `Speak Up` in new marketing effort
01 Mar 2024 //
ENDPTS
Insmed To Present at Three March Conferences
29 Feb 2024 //
PRESS RELEASE
Actress Jane Seymour and Insmed Raise Awareness of "Unseenism"
28 Feb 2024 //
PRESS RELEASE
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Result
22 Feb 2024 //
PRESS RELEASE
Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference
08 Feb 2024 //
PRESS RELEASE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
02 Feb 2024 //
PR NEWSWIRE
Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
05 Jan 2024 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04 Jan 2024 //
PRESS RELEASE
Insmed To Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 Dec 2023 //
PR NEWSWIRE
